{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lung+Cancer&q=KRAS",
    "query": {
      "q": "KRAS",
      "condition": "Lung Cancer"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 259,
    "total_pages": 26,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lung+Cancer&q=KRAS&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-07-24T13:46:36.318Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01168973",
      "title": "A Study of Chemotherapy and Ramucirumab Versus Chemotherapy Alone in Second Line Non-Small Cell Lung Cancer (NSCLC) Participants Who Received Prior First Line Platinum-based Chemotherapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Ramucirumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo (for Ramucirumab)",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1253,
      "start_date": "2010-12",
      "completion_date": "2016-08",
      "has_results": true,
      "last_update_posted_date": "2019-09-25",
      "last_synced_at": "2026-07-24T13:46:36.318Z",
      "location_count": 97,
      "location_summary": "Phoenix, Arizona • Sedona, Arizona • Fayetteville, Arkansas + 93 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Sedona",
          "state": "Arizona"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Alhambra",
          "state": "California"
        },
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01168973"
    },
    {
      "nct_id": "NCT07650357",
      "title": "A Study of CLSP 5282 in HLA-A*03:01 Positive Adult Patients With Solid Tumors (SENTINEL-101)",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumor",
        "Non Small Cell Lung Cancer",
        "Pancreatic Carcinoma",
        "Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "CLSP-5282",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Clasp Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 140,
      "start_date": "2026-07",
      "completion_date": "2029-07",
      "has_results": false,
      "last_update_posted_date": "2026-06-16",
      "last_synced_at": "2026-07-24T13:46:36.318Z",
      "location_count": 4,
      "location_summary": "Durham, North Carolina • Philadelphia, Pennsylvania • Nashville, Tennessee + 1 more",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07650357"
    },
    {
      "nct_id": "NCT05815173",
      "title": "Ladarixin With Sotorasib in Advanced NSCLC",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation"
      ],
      "interventions": [
        {
          "name": "Sotorasib",
          "type": "DRUG"
        },
        {
          "name": "Ladarixin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 40,
      "start_date": "2023-08-01",
      "completion_date": "2027-08",
      "has_results": false,
      "last_update_posted_date": "2025-12-30",
      "last_synced_at": "2026-07-24T13:46:36.318Z",
      "location_count": 6,
      "location_summary": "Garden City, New York • Mineola, New York • New Hyde Park, New York + 1 more",
      "locations": [
        {
          "city": "Garden City",
          "state": "New York"
        },
        {
          "city": "Mineola",
          "state": "New York"
        },
        {
          "city": "New Hyde Park",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05815173"
    },
    {
      "nct_id": "NCT02071862",
      "title": "Study of the Glutaminase Inhibitor CB-839 in Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumors",
        "Triple-Negative Breast Cancer",
        "Non Small Cell Lung Cancer",
        "Renal Cell Carcinoma",
        "Mesothelioma",
        "Fumarate Hydratase (FH)-Deficient Tumors",
        "Succinate Dehydrogenase (SDH)-Deficient Gastrointestinal Stromal Tumors (GIST)",
        "Succinate Dehydrogenase (SDH)-Deficient Non-gastrointestinal Stromal Tumors",
        "Tumors Harboring Isocitrate Dehydrogenase-1 (IDH1) and IDH2 Mutations",
        "Tumors Harboring Amplifications in the cMyc Gene"
      ],
      "interventions": [
        {
          "name": "CB-839",
          "type": "DRUG"
        },
        {
          "name": "Pac-CB",
          "type": "DRUG"
        },
        {
          "name": "CBE",
          "type": "DRUG"
        },
        {
          "name": "CB-Erl",
          "type": "DRUG"
        },
        {
          "name": "CBD",
          "type": "DRUG"
        },
        {
          "name": "CB-Cabo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Calithera Biosciences, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 210,
      "start_date": "2014-02",
      "completion_date": "2019-03",
      "has_results": false,
      "last_update_posted_date": "2022-07-20",
      "last_synced_at": "2026-07-24T13:46:36.318Z",
      "location_count": 13,
      "location_summary": "San Francisco, California • Stanford, California • Sarasota, Florida + 7 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02071862"
    },
    {
      "nct_id": "NCT05370469",
      "title": "Real-Time Monitoring of Symptoms in Lung Cancer Patients Receiving Oral Targeted Therapies",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Lung Cancer",
        "EGFR Gene Mutation",
        "EGFR",
        "ALK Gene Mutation",
        "RET Gene Mutation",
        "MET Gene Mutation",
        "KRAS Mutation-Related Tumors",
        "BRAF",
        "ROS1 Gene Mutation"
      ],
      "interventions": [
        {
          "name": "Sensus Smartwatch Application",
          "type": "OTHER"
        },
        {
          "name": "RX Cap",
          "type": "DEVICE"
        },
        {
          "name": "Fitbit Sense",
          "type": "DEVICE"
        },
        {
          "name": "Surveys",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DEVICE"
      ],
      "sponsor": "University of Virginia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2022-08-25",
      "completion_date": "2026-05",
      "has_results": false,
      "last_update_posted_date": "2025-11-25",
      "last_synced_at": "2026-07-24T13:46:36.318Z",
      "location_count": 1,
      "location_summary": "Charlottesville, Virginia",
      "locations": [
        {
          "city": "Charlottesville",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05370469"
    },
    {
      "nct_id": "NCT06024174",
      "title": "A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Solid Tumors"
      ],
      "interventions": [
        {
          "name": "BMS-986466",
          "type": "DRUG"
        },
        {
          "name": "Adagrasib",
          "type": "DRUG"
        },
        {
          "name": "Cetuximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2023-11-09",
      "completion_date": "2024-05-13",
      "has_results": true,
      "last_update_posted_date": "2025-07-22",
      "last_synced_at": "2026-07-24T13:46:36.318Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • Athens, Georgia • Hackensack, New Jersey + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Athens",
          "state": "Georgia"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        },
        {
          "city": "Morristown",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06024174"
    },
    {
      "nct_id": "NCT02022982",
      "title": "PALBOCICLIB + PD-0325901 for NSCLC & Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "KRAS Mutant Non-Small Cell Lung Cancer",
        "Solid Tumors"
      ],
      "interventions": [
        {
          "name": "Palbociclib",
          "type": "DRUG"
        },
        {
          "name": "PD-0325901",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2014-01",
      "completion_date": "2021-06-30",
      "has_results": false,
      "last_update_posted_date": "2024-03-19",
      "last_synced_at": "2026-07-24T13:46:36.318Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02022982"
    },
    {
      "nct_id": "NCT04470674",
      "title": "Study of Durvalumab or Durvalumab Plus Chemotherapy in Kras Mutation Positive and PD-L1 High (≥ 50%) NSCLC Patients",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lung Cancer",
        "Non-small Cell Lung Cancer",
        "PD-L1 Gene Mutation",
        "KRAS Activating Mutation"
      ],
      "interventions": [
        {
          "name": "Durvalumab",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Pemetrexed",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Shirish M Gadgeel",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2021-04-06",
      "completion_date": "2021-06-08",
      "has_results": false,
      "last_update_posted_date": "2022-03-03",
      "last_synced_at": "2026-07-24T13:46:36.318Z",
      "location_count": 1,
      "location_summary": "Detroit, Michigan",
      "locations": [
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04470674"
    },
    {
      "nct_id": "NCT06625775",
      "title": "Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor, Adult",
        "Metastatic Breast Cancer",
        "Advanced Breast Cancer",
        "HER2 Mutation-Related Tumors",
        "HER2-positive Metastatic Breast Cancer",
        "KRAS Mutant Metastatic Colorectal Cancer",
        "Metastatic Lung Cancer",
        "Metastatic Colorectal Cancer",
        "Advanced Lung Cancer",
        "HR-positive, HER2-negative Advanced Breast Cancer",
        "HER2-positive Advanced Breast Cancer"
      ],
      "interventions": [
        {
          "name": "BBO-10203",
          "type": "DRUG"
        },
        {
          "name": "Trastuzumab",
          "type": "DRUG"
        },
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        },
        {
          "name": "Ribociclib",
          "type": "DRUG"
        },
        {
          "name": "FOLFOX",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 392,
      "start_date": "2024-10-29",
      "completion_date": "2028-11",
      "has_results": false,
      "last_update_posted_date": "2026-06-23",
      "last_synced_at": "2026-07-24T13:46:36.318Z",
      "location_count": 19,
      "location_summary": "Duarte, California • Los Angeles, California • San Diego, California + 13 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06625775"
    },
    {
      "nct_id": "NCT06105021",
      "title": "Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Pancreatic Ductal Adenocarcinoma",
        "Non-Small Cell Lung Cancer",
        "Colorectal Cancer",
        "Solid Tumor",
        "KRAS G12V"
      ],
      "interventions": [
        {
          "name": "AFNT-211",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Affini-T Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2024-03-06",
      "completion_date": "2029-12",
      "has_results": false,
      "last_update_posted_date": "2025-07-30",
      "last_synced_at": "2026-07-24T13:46:36.318Z",
      "location_count": 10,
      "location_summary": "Los Angeles, California • New Haven, Connecticut • New York, New York + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06105021"
    }
  ]
}